UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD., CELLTRION INC,
and BIOCON BIOLOGICS INC.
Petitioners,

v.

REGENERON PHARMACEUTICALS, INC.
Patent Owner.

Patent No. 11,253,572

Inter Partes Review No. IPR2023-00884[1]

PATENT OWNER'S UPDATED EXHIBIT LIST

[1] IPR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.

Updated Exhibit List for *Inter Partes* Review of U.S. Patent No. 11,253,572

Exhibit No.	Exhibit Description
2001	Expert Declaration of Richard Manning, Ph.D., *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, IPR2021-00881, Ex. No. 2052 (Feb. 11, 2022)
2002	EYLEA® Label (rev. Oct. 2014)
2003	Trial Transcript (unsealed portions), *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.)
2004	Press Release, *Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration*, Regeneron Pharmaceuticals, Inc. (Mar. 27, 2007)
2005	Email from George Yancopoulos to Murray Goldberg re Top Line sum for PR (Mar. 22, 2007)
2006	Interim Analysis of Phase 2 Study of VEGF Trap in AMD patients (Mar. 22, 2007) (Attachment to Ex.2005)
2007	George D. Yancopoulos, VEGF Trap : Scientific Background, BSP / REGN Kick-Off (Feb. 16, 2007)
2008	Email from Kathleen Lawrence re Decisions & Actions: AMD Ph3 Program Mtg – 4/2/07 (Apr. 2, 2007)
2009	Email from George Yancopoulos to Darlene Jody re Summary of issues for call: AMD P3 Planning with enclosed outline attached (Apr. 4, 2007)
2010	Email from Robert Terifay to George Yancopoulos re VGTeye VIEW 430 presentation (Nov. 19, 2010)
2011	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) - VIEW 1 and VIEW 2 – 1-Year Results (Attachment to Ex.2010)
2012	Regeneron Pharmaceuticals, *Phase 1 Study of VEFT Trap in Patients With Diabetic Macular Edema*, https://clinicaltrials.gov/study/NCT00320814 (last updated Jun. 10, 2011)
2013	Regeneron, *Clinical Study Concept - Ophthalmology-Diabetic Macular Edema-Phase 2-IVT-VGFT-OD-0706* (updated May 19, 2008)
2014	Diana V. Do et al., *One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema*, 119 OPHTHALMOLOGY 1658-1665 (Aug. 2012).

Exhibit No.	Exhibit Description
2015	DA VINCI – DME And VEGF Trap-Eye: Investigation of Clinical Impact: One Year Data (Dec. 8, 2010) (attachment to Ex.2024)
2016	Regeneron Pharmaceuticals, *DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] Investigation of Clinical Impact (DA VINCI)*, https://clinicaltrials.gov/study/NCT00789477 (last updated Sep. 9, 2014)
2017	Email from Caroline Saxton re Data Review (Feb. 1, 2010)
2018	Regeneron Pharmaceuticals, Inc., *VGFT-OD-0706 Week 24 Topline Results* (Feb. 1, 2010) (attachment to Ex.2017)
2019	DRAFT – DA VINCI – 6-Month Primary Endpoint (Feb. 1, 2010) (attachment to Ex.2017)
2020	Regeneron Pharmaceuticals, Inc., *VEGF Trap-Eye Shows Positive Results in a Phase 2 Study in Patients With Diabetic Macular Edema* (Feb. 18, 2010)
2021	Email from Alyson Berliner to Dave Brown re ARVO late breakers (Mar. 1, 2010)
2022	*DA VINCI: DME And VEGF Trap-Eye: Investigation of Clinical Impact: Phase 2 study in patients with Diabetic Macular Edema (DME)* (Mar. 1, 2010) (Attachment to Ex.2021)
2023	Email from Dave Brown to Alyson Berliner and James Major re ARVO abstract (Mar. 3, 2010)
2024	Email from Caroline Saxton re Slides and tables – DaVinci (Dec. 8, 2010)
2025	U.S. Provisional Patent Application No. 61/434,836 (Jan. 21, 2011)
2026	Mylan Pharmaceuticals Inc.'s Answer, Defenses, and Counterclaims to Plaintiff's Complaint, *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 47 (filed Aug. 25, 2022)
2027	Stipulation and Order Joining Biocon Biologics Inc. as Defendant, *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 523 (filed Jun. 5, 2023)
2028	Complaint for Patent Infringement, *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 1 (filed Aug. 2, 2022)

Exhibit No.	Exhibit Description
2029	Order on Claim Construction, *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 427 (filed Apr. 19, 2023)
2030	Scheduling Order, *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 87 (filed Oct. 25, 2022)
2031	Regeneron's Stipulation Regarding Summary Judgment and Case Narrowing, *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 433 (filed Apr. 27, 2023)
2032	Defendant's Opening Post Trial Brief - Issues Where Defendants Bear the Burden of Proof, *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 576 (filed July 7, 2023)
2033	Order Setting Briefing Schedule, *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 514 (filed May 30, 2023)
2034	Transcript of the Status Conference held on Sept. 28, 2022, *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 90 (filed Nov. 2, 2022)
2035	Email from George Yancopoulos re DME Phase 2 – ALL TABLES (Feb. 2, 2010)
2036	DME Target Product Profile - VEGF Trap-Eye (Sept. 26, 2007)
2037	Clinical Development & Regulatory Affairs Weekly Update (Oct. 29, 2010)
2038	Clinical Development & Regulatory Affairs Weekly Update (Dec. 3, 2010)
2039	Email from George Yancopoulos re DME PLANS & FDA meeting pre-discussion (Jan. 9, 2008)
2040	MEMO re Guidance From Bayer/ REGN Sr. Management Regarding Additional Indications in Ophthalmology from George Yancopoulos to Bayer/REGN Joint Development Group (Mar. 28, 2008)
2041	Action Items by GD Yancopoulos - Bayer/REGN JSC (Feb. 15, 2008)
2042	Email from Yuhwen Soo to George Yancopoulos re Can you send me that slide you made combining the VA curves for View1 & View2 (Nov. 20, 2010)

Exhibit No.	Exhibit Description
2043	Vascular Endothelial Growth Factor (VEGF): Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)—VIEW1 + VIEW 2: 1-Year Results (Nov. 20, 2010) (Attachment to Ex.2042)
2044	Email from Michael Aberman to George Yancopoulos and Leonard Schleifer re Press Release (Nov. 19, 2010)
2045	Regeneron, *Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration* (Nov. 19, 2010) (Attachment to Ex.2044)
2046	U.S. Food & Drug Administration, *22 Case Studies Where Phase 2 and Phase 3 Trials Had Divergent Results* (Jan. 2017)
2047	VEGF Trap-Eye in Wet AMD - CLEAR-IT 2: Summary of One-Year Key Results, Presented at 2008 Retina Society Meeting, Scottsdale, Arizona (Sep. 28, 2008)
2048	Regeneron Pharmaceuticals, Inc., *A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME)* (Issued Jan. 28, 2009)
2049	Appendix to Heier et al., *Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-Related Macular Degeneration*, 119 OPHTHALMOLOGY 2537 (2012)
2050	*Retinal Physician Symposium Covers Broad Range of Topics*, Retinal Physician (Sept. 1, 2006), https://www.retinalphysician.com/issues/2006/september2006/retinal-physician-symposium-covers-broad-range-of
2051	Prema Abraham et al., *Randomized, Double-Masked, ShamControlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2*, 150 AM. J. OPHTHALMOLOGY 315 (2010)
2052	FDA, *Step 3: Clinical Research,* https://www.fda.gov/patients/drug-development-process/step-3-clinical-research (last accessed Aug. 23, 2023)
2053	Prosecution History of U.S. Patent App. No. 16/159,282 B2
2054	Anant Pai et al., *Current concepts in intravitreal drug therapy for diabetic retinopathy*, 24 SAUDI J. OPHTHALMOLOGY 143 (June 30, 2010)

Exhibit No.	Exhibit Description
2055	David M. Brown et al., *Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two phase Ill Trials*, 120 OPHTHALMOLOGY 2013 (2013)
2056	Jean-Francois Korobelnik et al., *Intravitreal Aflibercept for Diabetic Macular Edema*, 121 OPHTHALMOLOGY 2247 (2014)
2057	Quan Dong Nguyen et al., *Ranibizumab for Diabetic Macular Edema, Results from 2 Phase Ill Randomized Trials: RISE and RIDE,* 119 OPHTHALMOLOGY 789 (2012)
2058	Ursula Schmidt-Erfurth et al., *Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema.* 121 OPHTHALMOLOGY 1045 (2014)
2059	Default Protective Order
2060	Declaration of Kira A. Davis in Support of Motion for Admission *Pro Hac Vice* ("Davis Decl.")
2061	Declaration of Daralyn J. Durie in Support of Motion for Admission *Pro Hac Vice* ("Durie Decl.")
2062	Deposition Transcript of Edward Chaum, M.D., Ph.D. (January 5, 2024)
2063	Declaration of George Yancopoulos, M.D., PH.D. (February 19, 2024) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2064	Declaration of Karen Chu (February 19, 2024) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2065	Declaration of Michael W. Stewart, M.D. (February 21, 2024)
2066	Declaration of David M. Brown, M.D. (February 21, 2024)
2067	Declaration of Richard Manning, Ph.D. (February 22, 2024) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2068	Press Release, Regeneron, *Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases* (October 18, 2006)
2069	Regeneron/Bayer Alliance, Internal Kick-Off Meeting (November 8, 2006) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2070	Email from Robert Terifay to Leonard Schleifer and George Yancopoulos (March 22, 2007) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Exhibit No.	Exhibit Description
2071	Email from Peter Powchik to George Yancopoulos (March 22, 2007)
2072	PowerPoint Presentation (Attachment to Ex.2071) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2073	PowerPoint Presentation (Attachment to Ex. 2074) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2074	Email from George Yancopoulos to Leonard Schleifer (March 22, 2007)
2075	Email from George Yancopoulos to Darlene Jody (April 10, 2007) – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2076	CLEAR-IT 3 Clinical Trial Protocol – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2077	Email from Alyson Berliner to Dave Brown (March 1, 2020)
2078	Email from Dave Brown to Alyson Berliner; Robert Vitti; James Major (March 2, 2010)
2079	Draft of document titled DA VINCI: DME and VEGF Trap-Eye: Investigation of Clinical Impact: Phase 2 study in patients with Diabetic Macular Edema (DME)
2080	Document titled DA VINCI: DME and VEGF Trap-Eye: Investigation of Clinical Impact: Phase 2 study in patients with Diabetic Macular Edema (DME)
2081	Curriculum Vitae of David Mark Brown MD FACS
2082	David M. Brown et al., *Ranibizumab versus verteporfin for neovascular age-related macular degeneration*, New England Journal of Medicine, 355(14), 1432-1444 (2006)
2083	Philip J. Rosenfeld et al., *Ranibizumab for neovascular age-related macular degeneration,* New England Journal of Medicine, 355(14), 1419-1431 (2006)
2084	Press Release, *Genentech, Inc. Submits Biologics License Application for FDA Review of Lucentis(TM) In Wet Age-Related Macular Degeneration* (Dec. 30, 2005)
2085	Jonathan P. Levine et al., *Macular Hemorrhage in Neovascular Age-Related Macular Degeneration After Stabilization with Antiangiogenic Therapy*, 29 Retina, 1074-79 (2009)

Exhibit No.	Exhibit Description
2086	Irene Barbazetto et al., *Dosing Regimen and The Frequency of Macular Hemorrhages in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab*, 30 RETINA 1376-85 (2010)
2087	Daniele Cruz, *PIER Data Suggest a Need for Tailored Injection Schedule*, Ocular Surgery News, (Sept. 1, 2006)
2088	Press Release, Genentech, *FDA Approves Lucentis for the Treatment of Wet Age-Related Macular Degeneration* (June 30, 2006)
2089	Drugs@FDA, Lucentis Label, c. 2006, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf.
2090	Deposition Transcript of Edward Chaum, M.D., Ph.D. Volume 2 (February 2, 2024)
2091	Declaration of Jeffrey Spada (February 20, 2024)
2092	Document Containing Screenshots of Database – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2093	*Regeneron Pharms., Inc. v. Mylan Pharms. Inc. et al*, No. 22-cv-00061, Dkt. No. 692 (N.D.V.A. Jan. 31, 2024)
2094	Carl D. Regillo et al., *Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2,* 150 AM. J. OPHTHALMOLOGY 315 (2010)
2095	Candelaria Gomez-Manzano et al., *VEGF Trap induces antiglioma effect at different stages of disease*, Neuro-oncology, 10(6), 940-945 (2008)
2096	Curriculum Vitae of Michael W. Stewart, MD
2097	Geeta A. Lalwani et al., *A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study*, American journal of ophthalmology, 148(1), 43-58 (2009)
2098	F.G. Holz et al., SUSTAIN Study Group, *Safety and Efficacy of RanibizumabTreatment in Patients with Neovascular Age-Related Macular Degeneration: 12-MonthResults of the SUSTAIN Study*, Investigative Ophthalmology & Visual Science, 50(13), 3095-3095 (2009)
2099	RESERVED

Exhibit No.	Exhibit Description
2100	Eylea® Label (2016)
2101	Jean-Francois Korobelnik et al., *Intravitreal Aflibercept for Diabetic Macular Edema*, 121 OPHTHALMOLOGY 2247 (2014)
2102	LUCENTIS® Label (rev. Aug. 2012)
2103	Prema Abraham et al., *Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2,* 150 AM. J. OPHTHALMOLOGY 315-324 (2010)
2104	*Retinal Physician Symposium Covers Broad Range of Topics*, Retinal Physician (Sept. 1, 2006)
2105	Regeneron Pharmaceuticals, *DME and VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] Investigation of Clinical Impact (DA VINCI)*, https://classic.clinicaltrials.gov/ct2/show/study/NCT00789477
2106	Regeneron Press Release, *Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication* (Dec. 18, 2013)
2107	AVASTIN™ Label (2004)
2108	AVASTIN Approval Letter (February 26, 2004)
2109	Genentech, Inc., *A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)*, NCT00473330, ClinicalTrials.gov (December 14, 2023), https://www.clinicaltrials.gov/ct2/show/NCT00473330
2110	Genentech Press Release, *FDA Approves Genentech's Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States*, (April 17, 2017)
2111	LUCENTIS® Label (2017)
2112	Sarah Whelan, *What is Angiogenesis?*, Technology Networks (July 6, 2022)
2113	Matthew Dombrow et al., *Ocular Angiogenesis: The Science Behind the Symptoms*, Retinal Physician (2011)
2114	Joan W. Miller, VEGF: *From Discovery to Therapy: The Champalimaud Award Lecture*, Translational Vision Science & Technology, 5(2), 9-9 (2016)

Exhibit No.	Exhibit Description
2115	Macugen Approval Letter (December 14, 2004)
2116	Press Release, Genentech, *FDA Approves Genentech's Lucentis (Ranibizumab Injection) Prefilled Syringe* (October 14, 2016)
2117	RESERVED
2118	Press Release, Genentech, *Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration* (December 30, 2005)
2119	P Mitchell et al., *Ranibizumab (Lucentis) in Neovascular Age-Related Macular Degeneration: Evidence from Clinical Trials,* 94 BRIT. J. OPHTHALMOLOGY 2-13 (2009)
2120	Donald S. Fong et al., *Diabetic Retinopathy*, Diabetes Care, 27 (10), 2540-2553 (2004).
2121	Early Treatment Diabetic Retinopathy Study Research Group, *Early photocoagulation for diabetic retinopathy: ETDRS Report Number 9*, Ophthalmology, 98(5), 766-785 (1991)
2122	Diabetic Retinopathy Study Research Group, *Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8*, Ophthalmology, 88(7), 583-600 (1981)
2123	Ovidiu Musat et al., *Diabetic macular edema*, Romanian Journal of Ophthalmology, 59(3), 133 (2015)
2124	Early Treatment Diabetic Retinopathy Study Research Group, *Photocoagulation for Diabetic Macular Edema, ETDRS report Number 1*, *Arch Ophthalmol*, *103*(12), 1796-1806 (1985)
2125	Anita Prasad, The DRCR Network Aids DR Treatment, *Review of Ophthalmology* (2006)
2126	Pedro Romero-Aroca et al., *Laser treatment for diabetic macular edema in the 21st century*, Current Diabetes Reviews, 10(2), 100-112 (2014)
2127	Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, *Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report 1*, Archives of Ophthalmology, 117(10), 1329-1345 (1999)
2128	FDA, *Step 3: Clinical Research,* https://www.fda.gov/patients/drug-development-process/step-3-clinical-research (last accessed Aug. 23, 2023)

Exhibit No.	Exhibit Description
2129	Press Release, BioSpace, *Opko Health, Inc. Announces Update on Phase III Clinical Trial of Bevasiranib; Company Decided to Terminate Clinical Study* (March 6, 2009)
2130	Press Release, Opko Health, *Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD* (July 11, 2007)
2131	Press Release, Opko Health, *OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials* (December 6, 2007)
2132	Dhyana Sharma et al., *Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases*, Investigative Ophthalmology & Visual Science, 64(5), 28-28 (2023)
2133	How to Read a Study Record, ClinicalTrials.gov, available at https://clinicaltrials.gov/study-basics/how-to-read-study-record#record-history-tab (last updated Jan. 9, 2024).
2134	Archived Webpage Re: Clinical Trial No. NCT00473330
2135	Sarah Whelan, *What is Angiogenesis?*, Technology Networks (July 6, 2022)
2136	Thomas H. Adair & Jean-Pierre Montani, *Angiogenesis*, Morgan & Claypool Life Sciences (2011)
2137	Michael J. Tolentino et al., *Intravitreous Injections of Vascular Endothelial Growth Factor Produce Retinal Ischemia and Microangiopathy in an Adult Primate*, Ophthalmology, 103(11), 1820-1828 (1996)
2138	David M. Brown et al., *Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial*, JAMA Ophthalmology, 139(9), 946-955 (2021)
2139	Jeffrey S. Heier et al., *Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies*, Ophthalmology, 123(11), 2376-2385 (2016)
2140	Drugs@FDA, Eylea label, 2/2023, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125387s075lbl.pdf
2141	American Society of Retina Specialists, "2015 Preferences and Trends (PAT) Survey," c. 2015 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Exhibit No.	Exhibit Description
2142	American Society of Retina Specialists, "2016 Preferences and Trends (PAT) Survey," c. 2016 - CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2143	Regeneron, "DME Market Assessment," 8/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2144	Regeneron, "Q2 2020 Performance Update," 7/2020 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2145	U.S. Patent Provisional Application No. 61/432,245
2146	U.S. Patent No. 11,730,794 B2
2147	American Society of Retina Specialists, "2009 Preferences and Trends Membership Survey," c. 2009 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2148	Beovu label, 10/2019, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf
2149	Beovu label, 12/2022, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s017lbl.pdf
2150	Centers for Disease Control and Prevention, *Vision Loss: A Public Health Problem*, 12/19/2022, https://www.cdc.gov/visionhealth/basic_information/vision_loss.htm
2151	Centers for Medicare & Medicaid Services Website, Medicare Physician & Other Practitioners - by Provider and Service, https://data.cms.gov/provider-summary-by-type-of-service/medicare-physician-other-practitioners/medicare-physician-other-practitioners-by-provider-and-service
2152	Drugs.com Website, Eylea FDA Approval History, https://www.drugs.com/history/eylea.html (accessed 1/16/2024)
2153	Eylea label, 5/2019, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125387s061lbl.pdf
2154	Eylea label, 9/2012, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125387s004lbl.pdf

Exhibit No.	Exhibit Description
2155	Guha, Rahul, Jian Li, and Andrea L. Scott (2009), *The Economics of Commercial Success in Pharmaceutical Patent Litigation*, Landslide 1(5) (2009)
2156	Lucentis label, 3/2018, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125156s117lbl.pdf
2157	Lucentis label, 6/2010, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125156s053lbl.pdf
2158	Manning, Richard, et al. (2015), *Similar Products at Different Prices: Can Biopharmaceutical Companies Segment Markets?*, International Journal of the Economics of Business 22(2): 231–243 (2015)
2159	NCI, Second-Line Therapy, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/second-line-therapy (accessed 1/16/2024)
2160	Regeneron Press Release, *Eylea (Aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)*, 7/29/2014
2161	Regeneron Website, History, https://www.regeneron.com/about/history (accessed 1/15/2024).
2162	Regeneron, "DME Market Assessment Q1 2015," 4/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2163	Regeneron, "DME Market Assessment Q1 2016," 4/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2164	Regeneron, "DME Market Assessment Q1 2017," 5/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2165	Regeneron, "DME Market Assessment Q1 2018," 5/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2166	Regeneron, "DME Market Assessment Q2 2015," 8/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Exhibit No.	Exhibit Description
2167	Regeneron, "DME Market Assessment Q2 2016," 8/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2168	Regeneron, "DME Market Assessment Q2 2017," 7/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2169	Regeneron, "DME Market Assessment Q2 2018," 7/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2170	Regeneron, "DME Market Assessment Q3 2015," 11/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2171	Regeneron, "DME Market Assessment Q3 2016," 10/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2172	Regeneron, "DME Market Assessment Q3 2017," 10/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2173	Regeneron, "DME Market Assessment Q4 2014," 1/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2174	Regeneron, "DME Market Assessment Q4 2015," 2/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2175	Regeneron, "DME Market Assessment Q4 2016," 1/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2176	Regeneron, "DME Market Assessment Q4 2017," 2/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2177	Regeneron, "DME Market Assessment Wave 3, Q3 2014," 11/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2178	Regeneron, "DME Market Assessment, Benchmark Wave," 11/8/2013 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Exhibit No.	Exhibit Description
2179	Regeneron, "Physician ATU: Q1 2015," 4/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2180	Regeneron, "Physician ATU: Q2 2015," 7/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2181	Regeneron, "Physician ATU: Q3 2014," 11/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2182	Regeneron, "Physician ATU: Q3 2015," 11/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2183	Regeneron, "Physician ATU: Q4 2014," 1/2015 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2184	Regeneron, "Physician ATU: Q4 2015," 1/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2185	Regeneron, "Physician ATU: Wave 2," 2/2013 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2186	Regeneron, "Physician ATU: Wave 4," 8/6/2013 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2187	Regeneron, "Physician ATU: Wave 5," 11/2013 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2188	Regeneron, "Physician ATU: Wave 6," 1/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2189	Regeneron, "Physician ATU: Wave 7," 4/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2190	Regeneron, "Physician ATU: Wave 8," 8/2014 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Exhibit No.	Exhibit Description
2191	Regeneron, "Q1 2019 Performance Update Wet AMD, DME, & MEfRVO," 5/2019 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2192	Regeneron, "Q1 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME," 4/2020 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2193	Regeneron, "Q2 2019 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME," 8/2019 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2194	Regeneron, "Q3 2018 Performance Update Wet AMD, DME, & MEfRVO," 11/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2195	Regeneron, "Q3 2019 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME," 11/2019 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2196	Regeneron, "Q3 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME," 11/2020 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2197	Regeneron, "Q4 2018 Performance Update Wet AMD, DME, & MEfRVO," 2/2019 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2198	Regeneron, "Q4 2019 Performance Update Wet AMD, DME, & MEfRVO," 1/2020 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2199	Regeneron, "Q4 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME," 1/29/2021 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2200	RESERVED
2201	RESERVED
2202	RESERVED
2203	RESERVED
2204	RESERVED
2205	RESERVED
2206	RESERVED
2207	RESERVED
2208	RESERVED
2209	RESERVED

Exhibit No.	Exhibit Description
2210	RESERVED
2211	RESERVED
2212	RESERVED
2213	RESERVED
2214	Regeneron, "US Eylea P&L LTD," c. 2021 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2215	Regeneron, "Wet AMD Physician ATU: Q1 2016," 4/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2216	Regeneron, "Wet AMD Physician ATU: Q1 2017," 4/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2217	Regeneron, "Wet AMD Physician ATU: Q1 2018," 5/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2218	Regeneron, "Wet AMD Physician ATU: Q2 2016," 8/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2219	Regeneron, "Wet AMD Physician ATU: Q2 2017," 7/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2220	Regeneron, "Wet AMD Physician ATU: Q2 2018," 7/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2221	Regeneron, "Wet AMD Physician ATU: Q3 2016," 10/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2222	Regeneron, "Wet AMD Physician ATU: Q3 2017," 10/2017 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2223	Regeneron, "Wet AMD Physician ATU: Q4 2016," 1/2016 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2224	Regeneron, "Wet AMD Physician ATU: Q4 2017," 1/2018 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Exhibit No.	Exhibit Description
2225	Regeneron, "Wave 1 2021 Performance Update Wet AMD, DME, MEfRVO, and DR w/out DME," 9/2021 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2226	Regeneron, ATU Sales Share Data: All Indications, c. 2021
2227	Regeneron, ATU Sales Share Data: BRVO, c. 2021
2228	Regeneron, ATU Sales Share Data: CRVO, c. 2021
2229	Regeneron, ATU Sales Share Data: DME, c. 2021
2230	Regeneron, ATU Sales Share Data: DR w/o DME, c. 2021
2231	Regeneron, ATU Sales Share Data: Wet AMD, c. 2021
2232	Regeneron, Eylea Gross & Net Sales P&L YTD, c.2021 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2233	Regeneron, Form 10-K, 2020
2234	Susvimo Label, 10/2021, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761197s000lbl.pdf
2235	Susvimo Label, 4/2022, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761197s002lbl.pdf
2236	Vabysmo Label, 1/2022, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf
2237	Vabysmo Label, 1/2023, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s001lbl.pdf
2238	Vestrum, Anti-VEGF Category Sales Shares, c. 2/2022 – CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER
2239	World Health Organization, "Blindness and Vision Impairment Fact Sheet," 8/10/2023, https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment
2240	Declaration of Nathaniel E Frank-White (February 15, 2024)
2241 [NEW]	Declaration of Matthew M. Wilk in Support of this Motion for Admission *Pro Hac Vice* ("Wilk Decl.").
2242 [NEW]	Declaration of Jeremy Cobb in Support of this Motion for Admission *Pro Hac Vice* ("Cobb Decl.").

Date: March 15, 2024

Respectfully Submitted,

By: /Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105
Tel: (415) 268-6053
ABrausa@mofo.com

Counsel for Patent Owner

Certificate of Service (37 C.F.R. § 42.6(e)(4))

I hereby certify that the attached PATENT OWNER'S UPDATED EXHIBIT LIST was served on the date listed below via email (by agreement) upon the following counsel of record for Petitioners:

Raymond N. Nimrod (Reg. No. 31,987)
Matthew A. Traupman (Reg. No. 50,832)
Elliot Choi (*pro hac vice* granted)
Zachariah Summers (*pro hac vice* granted)
Sarah Cork (*pro hac vice* to be applied for)
Landon Andrew Smith (Reg. No. 79,248)
QUINN EMANUEL URQUHART
& SULLIVAN, LLP
51 Madison Ave., 22nd Floor
New York, NY 10010
General Tel: (212) 849-7000
Direct Tel: (212) 849-7322
Fax: (212) 849-7100
Email: raynimrod@quinnemanuel.com
Email: matthewtraupman@quinnemanuel.com
Email: elliotchoi@quinnemanuel.com
Email: zachsummers@quinnemanuel.com
Email: landonsmith@quinnemanuel.com
Email: qe-samsungbioepis@quinnemanuel.com

Paul J. Molino (Reg. No. 45,350)
William A. Rakoczy (*pro hac vice* to be filed)
Deanne M. Mazzochi (Reg. No. 50,158)
Heinz J. Salmen (*pro hac vice* to be filed)
Eric R. Hunt (*pro hac vice* to be filed)
Neil B. McLaughlin (Reg. No. 70,810)
Lauren M. Lesko (*pro hac vice* to be filed)
L. Scott Beall (Reg. No. 52,601)
Thomas H. Ehrich (Reg. No. 67,122)
Steven J. Birkos (Reg. No. 65,300)

Jake R. Ritthamel (*pro hac vice* to be filed)
Rakoczy Molino Mazzochi Siwik LLP
6 West Hubbard Street
Chicago, IL 60654
Telephone: (312) 527-2157
Facsimile: (312) 843-6260
MYL_REG_IPR@rmmslegal.com

Lora Green (Reg. No. 43,541)
Yahn-Lin Chu (Reg. No. 75,946)
Robert Cerwinski (to be admitted *pro hac vice*, pending)
Aviv Zalcenstein (to be admitted *pro hac vice*, pending)
Brigid Morris (to be admitted *pro hac vice*, pending)
Gemini Law LLP
40 W 24th Street, Suite 6N
New York, NY 10010
Tel.: 917-915-8832
Email: lgreen@geminilaw.com
Email: fchu@geminilaw.com
Email: rcerwinski@geminilaw.com
Email: azalcenstein@geminilaw.com
Email: bmorris@geminilaw.com

Dated: March 15, 2024

/Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287